Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.

Inclusion criteria: Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years Exclusion criteria: Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\& Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.